Literature DB >> 24113401

Near elimination of genital warts in Australia predicted with extension of human papillomavirus vaccination to males.

Igor A Korostil1, Hammad Ali, Rebecca J Guy, Basil Donovan, Matthew G Law, David G Regan.   

Abstract

BACKGROUND: The National Human Papillomavirus (HPV) Vaccination Program for females delivering the quadrivalent vaccine Gardasil has been included in the National Immunisation Program in Australia since 2007. Sentinel surveillance data show that genital wart incidence has been steadily declining since then. The objective of this study was to estimate the additional impact on genital warts as a result of male vaccination, which was approved by the Australian government in 2012 and commenced in 2013.
METHODS: We use a mathematical model of HPV transmission in the Australian heterosexual population to predict the impact of male vaccination on the incidence of genital warts.
RESULTS: Our model produced results that are consistent with the actual observed decline in genital warts and predicted a much lower incidence, approaching elimination, in coming decades with the introduction of male vaccination.
CONCLUSIONS: Results from our model indicate that the planned extension of the National HPV Vaccination Program to males will lead to the near elimination of genital warts in both the female and male heterosexual populations in Australia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24113401     DOI: 10.1097/OLQ.0000000000000030

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  12 in total

Review 1.  [HPV-induced anal lesions].

Authors:  U Wieland; A Kreuter
Journal:  Hautarzt       Date:  2015-06       Impact factor: 0.751

Review 2.  As through a glass, darkly: the future of sexually transmissible infections among gay, bisexual and other men who have sex with men.

Authors:  Mark Richard Stenger; Stefan Baral; Shauna Stahlman; Dan Wohlfeiler; Jerusha E Barton; Thomas Peterman
Journal:  Sex Health       Date:  2017-02       Impact factor: 2.706

3.  Human papillomavirus vaccination for boys.

Authors:  Stephany Quinn; Ran D Goldman
Journal:  Can Fam Physician       Date:  2015-01       Impact factor: 3.275

4.  Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014.

Authors:  Elaine W Flagg; Elizabeth A Torrone
Journal:  Am J Public Health       Date:  2017-11-21       Impact factor: 9.308

Review 5.  Strengthening the case for gender-neutral and the nonavalent HPV vaccine.

Authors:  Justin M Hintze; James P O'Neill
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-01-11       Impact factor: 2.503

6.  High HIV, HPV, and STI prevalence among young Western Cape, South African women: EVRI HIV prevention preparedness trial.

Authors:  Anna R Giuliano; Matthys H Botha; Michele Zeier; Martha E Abrahamsen; Richard H Glashoff; Louvina E van der Laan; Mary Papenfuss; Susan Engelbrecht; Maarten F Schim van der Loeff; Staci L Sudenga; Benji N Torres; Siegfried Kipping; Douglas Taylor
Journal:  J Acquir Immune Defic Syndr       Date:  2015-02-01       Impact factor: 3.731

Review 7.  Impact of HPV vaccination on anogenital warts and respiratory papillomatosis.

Authors:  Zoon Wangu; Katherine K Hsu
Journal:  Hum Vaccin Immunother       Date:  2016-05-23       Impact factor: 3.452

Review 8.  Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2014-07       Impact factor: 11.431

Review 9.  The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?

Authors:  Cyra Patel; Julia Ml Brotherton; Alexis Pillsbury; Sanjay Jayasinghe; Basil Donovan; Kristine Macartney; Helen Marshall
Journal:  Euro Surveill       Date:  2018-10

Review 10.  High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis.

Authors:  Nicole S L Yeo-Teh; Yoshiaki Ito; Sudhakar Jha
Journal:  Int J Mol Sci       Date:  2018-06-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.